Get the Stockscreener App
0.5437
8.74%
0.0437
After Hours:
.54
-0.0037
-0.68%
Century Therapeutics Inc stock is traded at $0.5437, with a volume of 657.52K.
It is up +8.74% in the last 24 hours and down -13.05% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.50
Open:
$0.5
24h Volume:
657.52K
Relative Volume:
1.36
Market Cap:
$42.95M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2374
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+33.33%
1M Performance:
-13.05%
6M Performance:
-65.37%
1Y Performance:
-80.86%
1-Day Range:
$0.50
$0.5572
1-Week Range:
$0.4091
$0.5572
52-Week Range:
$0.3418
$3.70
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5437 | 42.95M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MSN
Century Therapeutics to Host Live Chat on Preclinical Cell Therapy Programs Targeting Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics to Host Live Fireside Chat Focused on - GlobeNewswire
Century Therapeutics Unveils Next-Gen Cell Therapy Pipeline for Cancer and Autoimmune | IPSC Stock News - Stock Titan
American Century Companies Inc. Buys Shares of 105,337 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Sei Investments Co. Purchases New Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
American Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
American Century Companies Inc. Boosts Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World
American Century Companies Inc. Acquires 4,547 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
American Century Companies Inc. Purchases 13,916 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
American Century Companies Inc. Has $696,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by American Century Companies Inc. - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by American Century Companies Inc. - Defense World
American Century Companies Inc. Buys 24,090 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World
HC Wainwright Issues Positive Forecast for IPSC Earnings - Defense World
American Century Companies Inc. Acquires 39,932 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
American Century Companies Inc. Has $3.36 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
American Century Companies Inc. Buys 1,622 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MSN
American Century Companies Inc. Purchases 31,251 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
HC Wainwright Issues Pessimistic Forecast for Century Therapeutics (NASDAQ:IPSC) Stock Price - Defense World
H.C. Wainwright cuts Century Therapeutics target to $2 By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by American Century Companies Inc. - Defense World
American Century Companies Inc. Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by American Century Companies Inc. - Defense World
Guggenheim Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
What is Chardan Capital’s Estimate for IPSC FY2025 Earnings? - Defense World
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital - Defense World
William Blair Issues Optimistic Forecast for IPSC Earnings - The AM Reporter
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Q1 EPS Estimate for Century Therapeutics Boosted by Analyst - Defense World
Chardan Cuts Price Target on Century Therapeutics to $7 From $11, Keeps Buy Rating - MarketScreener
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN
Guggenheim Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - Defense World
Piper Sandler Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $2.00 - Defense World
Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating By Investing.com - Investing.com Canada
What is William Blair’s Estimate for IPSC Q3 Earnings? - Defense World
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Century Therapeutics Reports 2024 Financial Results and Strategic Updates - TipRanks
Leerink Partners Adjusts Price Target on Century Therapeutics to $8 From $13, Keeps Outperform Rating - Marketscreener.com
Viper Energy, Inc., a Subsidiary of Diamondback Energy, Inc., Schedules First Quarter 2025 Conference Call for May 6, 2025 - The Manila Times
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Century Therapeutics, Inc. SEC 10-K Report - TradingView
Century Therapeutics Announces Pipeline Re-Prioritization to Focus on Transformational Programs and Extends Cash Runway into Q4 2026 - Nasdaq
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Century Therapeutics Secures 2-Year Cash Runway with $220M War Chest - StockTitan
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of “Buy” from Analysts - The AM Reporter
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - Defense World
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Russotti Gregory | See Remarks |
Mar 10 '25 |
Sale |
0.61 |
2,360 |
1,451 |
272,573 |
| Farid Adrienne | Chief Operations Officer |
Mar 10 '25 |
Sale |
0.61 |
2,359 |
1,451 |
131,717 |
| Carr Douglas | SVP Finance & Operations |
Mar 10 '25 |
Sale |
0.61 |
1,240 |
763 |
315,556 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):